{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:09:06Z","timestamp":1789826946409,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:00:00Z","timestamp":1559779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014389","name":"Amarin Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014389","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.amjcard.2019.05.057","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T11:39:06Z","timestamp":1559821146000},"page":"696-701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid\/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study)"],"prefix":"10.1016","volume":"124","author":[{"given":"Michael","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold E.","family":"Bays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Granowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Ralph T.","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Juliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sephy","family":"Philip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2019.05.057_bib0001","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Kaptoge","year":"2010","journal-title":"Lancet"},{"issue":"25 Suppl 2","key":"10.1016\/j.amjcard.2019.05.057_bib0002","first-page":"S49","article-title":"2013 ACC\/AHA Guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0003","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1-full report","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0004","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa042000","article-title":"Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease","volume":"352","author":"Nissen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0006","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/CIRCULATIONAHA.106.628909","article-title":"Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial","volume":"114","author":"Morrow","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0007","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2017.02.004","article-title":"Potential benefits of eicosapentaenoic acid on atherosclerotic plaques","volume":"91","author":"Nelson","year":"2017","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0009","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.amjcard.2012.05.031","article-title":"Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)","volume":"110","author":"Ballantyne","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40256-012-0002-3","article-title":"Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies","volume":"13","author":"Bays","year":"2013","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0011","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jacl.2014.11.009","article-title":"Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)","volume":"9","author":"Ballantyne","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0012","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.atherosclerosis.2016.08.005","article-title":"Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies","volume":"253","author":"Ballantyne","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0013","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacl.2016.02.008","article-title":"Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies","volume":"10","author":"Ballantyne","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0014","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","article-title":"Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial)","volume":"108","author":"Bays","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0015","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1475-2840-12-100","article-title":"Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200\u2013500 mg\/dL), and on statin therapy at LDL-C goal: the ANCHOR study","volume":"12","author":"Brinton","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0016","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.plefa.2013.07.005","article-title":"Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study)","volume":"89","author":"Braeckman","year":"2013","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0017","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cpdd.84","article-title":"Pharmacokinetics of eicosapentaenoic acid in plasma and red blood cells after multiple oral dosing with icosapent ethyl in healthy subjects","volume":"3","author":"Braeckman","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0018","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.amjcard.2016.10.027","article-title":"Usefulness of icosapent ethyl (eicosapentaenoic acid ethyl ester) in women to lower triglyceride levels (results from the MARINE and ANCHOR trials)","volume":"119","author":"Mosca","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0019","first-page":"A15097","article-title":"Icosapent ethyl reduces potentially atherogenic lipid and inflammatory markers in high-risk statin-treated patients with stage 3 chronic kidney disease and persistent high triglycerides [abstract]","volume":"136","author":"Vijayaraghavan","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0020","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1089\/jwh.2017.6757","article-title":"Lipid effects of icosapent ethyl in women with diabetes mellitus and persistent high tiglycerides on statin treatment: ANCHOR trial subanalysis","volume":"27","author":"Brinton","year":"2018","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0021","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.atherosclerosis.2015.07.035","article-title":"Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis","volume":"242","author":"Borow","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0022","doi-asserted-by":"crossref","first-page":"A18549","DOI":"10.1161\/circ.126.suppl_21.A18549","article-title":"Effects of AMR101, a pure eicosapentaenoic omega-3 fatty acid, on the fatty acid profile in plasma and red blood cells in statin-treated patients with persistent high triglycerides (results from the ANCHOR study) [abstract]","volume":"126","author":"Braeckman","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0023","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jacl.2013.10.003","article-title":"Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial","volume":"8","author":"Kastelein","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0024","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12944-015-0100-8","article-title":"Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial","volume":"14","author":"Dunbar","year":"2015","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0025","unstructured":"Omtryg Medical Reviews Food and Drug Administration Website: Food and Drug Administration; Center for Drug Evaluation and Research, 2014."},{"key":"10.1016\/j.amjcard.2019.05.057_bib0026","unstructured":"Vascepa [package insert]. Bedminster, NJ: Amarin Pharma Inc., 2017."},{"key":"10.1016\/j.amjcard.2019.05.057_bib0027","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2019.05.057_bib0028","unstructured":"American Diabetes Association issues critical updates to the 2019 standards of medical care in diabetes. Arlington, VA, 2019."}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000291491930637X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000291491930637X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:30:09Z","timestamp":1757572209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000291491930637X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S000291491930637X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.05.057","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid\/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study)","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.05.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}